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Abstract Calcification of the media of arterial walls is
common in diabetes and is particularly associated with
distal symmetrical neuropathy. Arterial calcification also
complicates chronic kidney disease and is an independent
risk factor for cardiovascular and all-cause mortality. The
term calcification is not strictly accurate because the
morphological changes incorporate those of new bone
formation, i.e. ossification. The processes are complex,
but are closely related to those involved in bone homeo-
stasis, and it is relevant that calcification of the arterial wall
and osteopenia often co-exist. One particular factor linked
to the development of arterial calcification is distal
symmetrical neuropathy; indeed, it has been suggested that
neuropathy explains the distal distribution of arterial
calcification in diabetes. It has also been suggested that
the link with neuropathy results from loss of neuropeptides,
such as calcitonin gene-related peptide, which are inherent-
ly protective. The association between distal symmetrical
neuropathy and calcification of the arterial wall highlights
the fact that neuropathy may be an independent risk factor
for cardiovascular mortality.
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Abbreviations
BMP Bone morphogenetic protein
Cbfa1 Transcription factor core-binding protein
CGRP Calcitonin gene-related peptide
CVC Calcifying vascular cells
DSN Distal symmetrical neuropathy
MAC Medial artery calcification
MGP Matrix Gla protein
MSX-2 Msh homeobox 2
NF-κB Nuclear factor kappa-B
PPAR Peroxisome proliferator-activated receptor
RANK Receptor activator for nuclear factor κB
RANKL Receptor activator for nuclear factor κB ligand
TRAIL TNF-related apoptosis-inducing ligand
VEGF Vascular endothelial growth factor
VSMC Vascular smooth muscle cells
Introduction
Calcification of the media or medial artery calcification
(MAC) was first described by the German pathologist, J. G.
Mönckeberg, in 1903 [1] and is also known as Möncke-
berg’s sclerosis. Mönckeberg’s article pointed out that the
changes were most prevalent in the distal arteries of the
limbs [1]. MAC is frequently observed in patients with
diabetes and is associated with increased risk of nephrop-
athy, retinopathy, major amputation, coronary artery disease
and all-cause mortality [2, 3]. Many processes are involved
in the pathogenesis of MAC, which in diabetes is thought to
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be particularly associated with distal symmetrical neurop-
athy (DSN). The aim of this review is threefold: (1) to
provide an overview of the active and passive processes
involved in arterial wall calcification; (2) to highlight the
potential mechanisms linking DSN to MAC in diabetic
patients; and (3) to consider the implications of MAC in
clinical practice.
Calcification of the arterial intima and media
Calcification of the intima is a feature of atheroma
(atherosclerotic calcification), is eccentric, associated with
luminal narrowing and tends to be more proximal. In
contrast, MAC tends to be concentric and symmetrical, and
is a common feature of more distal arteries in diabetes.
Essentially, however, the change which takes place in both
cases is not limited to calcification by passive mineral
deposition, but involves active ossification and de novo
bone formation, as was first noted by Rudolf Virchow in
1863 (Fig. 1) [4]. No studies have been undertaken to
determine the relative frequencies with which passive
calcification and ossification may be observed. Intimal
calcification, however, tends to have the histological
features of endochondral bone formation, whereas MAC
is more typically membranous [5], although endochondral
bone formation can also be observed in MAC [6].
Numerous factors cause, trigger or exaggerate the process
of arterial calcification, and have been extensively studied
and reviewed in recent years [5, 7–10], mirroring to a large
extent factors that promote atherogenesis. They include:
physical intra-arterial forces; antigens stimulating immune
responses from the dendritic cells, T cells and macrophages
adjacent to the endothelium; oxidative stress; high ambient
glucose concentrations with increased AGE, insulin, reac-
tive oxygen species and oxidised LDL; pro-inflammatory
cytokines; and factors triggering the release of TGF-β.
Phosphate accumulation is important in chronic kidney
disease, as are vitamin D deficiency and hyperparathyroid-
ism. Arterial calcification is also potentiated by increases in
calcium and phosphate ions resulting from enhanced bone
turnover and is commonly associated with osteoporosis.
Moreover, calcification is influenced by several other local
growth factors (including IGF-1) and systemic hormones
(including oestrogens and thyroid hormones).
Although the factors leading to MAC in chronic kidney
disease have been well reviewed [11], those involved in
causing MAC in diabetes are more complex and less well
understood. The association between MAC and DSN in
diabetes is recognised, but the mechanisms underlying the
association, and its clinical significance, have not been
previously considered in detail.
Cellular aspects of arterial calcification
The cellular processes involved comprise differentiation of
cells with bone-forming (osteogenic) potential, matrix
vesicle formation and both apoptotic and non-apoptotic
calcification (Fig. 2).
Origin of bone forming (osteogenic) cells Osteogenic cells
are thought to be derived from pluripotential, mesenchymal
stem cells, which originate principally from the bone
marrow and are seeded from the circulation into the target
tissues, where they retain the capacity to differentiate and,
crucially in the process of arterial calcification, de-
differentiate and re-differentiate (or ‘trans-differentiate’)
into cells with different phenotypic features and functions
[12].
Mesenchymal stem cells respond to potentially harmful
stimuli by secreting bone morphogenetic proteins (BMPs),
which trigger the differentiation of osteogenic cells. BMP-2
was first shown to be associated with calcification in human
atherosclerotic plaques by Boström and colleagues [13]. A
complex nomenclature hampers understanding of these
processes, with cells of bone-forming potential variously
referred to by different researchers, depending on their
position in the arterial wall and their state of differentiation,
as pericytes, vascular smooth muscle cells (VSMCs),
calcifying vascular cells (CVCs) and adventitial cells.
VSMCs and CVCs are themselves derived from pericytes
and adventitial cells. Pericytes may differentiate along one
of several pathways into VSMCs and CVCs, endothelial
cells [14] and adipocytes [15].
Determinants of cellular differentiation BMPs induce oste-
ogenic change via a variety of transcription proteins
including Runx-related, transcription factor core-binding
protein (Cbfa1), msh homeobox 2 (MSX-2), osterix, and
Fig. 1 Cross-section through a human tibial artery with both small foci of
calcification and larger calcific deposits within the tunica media, stained
with Alizarin Red. Illustration kindly provided by M. Y. Alexander
(Cardiovascular Research Group, University of Manchester, UK)
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SRY (sex determining region Y)-box 9 (SOX9) [16]. MSX-
2 is required for membranous bone formation, whereas
Cbfa1 is necessary for osteoblastic transformation, neo-
vascularisation and endochondral ossification [17]. SOX9
may determine whether ensuing ossification is endochon-
dral or membranous in type [6]. The actions of BMPs on
target cells such as VSMCs are to some extent conflicting,
suggesting the existence of intrinsic autoregulatory and
overlapping mechanisms.
In response to BMP-2 and BMP-4, VSMCs ‘trans-
differentiate’ into non-contractile cells with bone-forming
capacity and acquire properties of osteoblasts, i.e. ability to
synthesise alkaline phosphatase, bone sialoprotein, osteo-
calcin and type I collagen [18]. It is likely that ‘trans-
differentiated’ VSMCs share with normal osteoblasts the
capacity to elaborate another TGF-β-related protein, name-
ly the pleiotropic hormone, activin-A, as well as its
glycoprotein antagonists, follistatin and follistatin-related
proteins [19, 20]. Activin-A production is another example
of the potential for complex autoregulation, as it inhibits
mineralisation. Activin-A is also involved in promoting
neovascularisation, where its actions are potentiated by
basic fibroblast growth factor-2. Activin-A and vascular
endothelial growth factor (VEGF) each upregulate produc-
tion of the other in bovine VSMCs in culture [21].
Intriguingly, BMP-2 and BMP-4 are also involved in the
early development of autonomic and somatic sensory
nerves, and in regulating levels of different neuropeptides
by modulation of specific peptidergic systems [22]. This
may be relevant to the putative role of autonomic and
somatic sensory nerves in regulation of calcification of the
arterial wall (see below).
Matrix vesicle formation Matrix vesicle formation is a
feature of normal osteogenesis [23]. The vesicles are just
over 100 nm in diameter and are enclosed in a tri-lamellar
membrane. They are rich in alkaline phosphatase, which
catalyses the breakdown of pyrophosphate, itself an
inhibitor of calcification. Phosphate is actively transported
into the vesicle by a sodium-dependent phosphate pump.
The pumping of phosphate ions into the vesicle is itself
potentiated by increased phosphate concentration in the
extracellular fluid, as occurs in states of enhanced bone
resorption and in chronic renal failure. Matrix vesicles also
contain calcium-binding proteins. The vesicle membrane
later disintegrates and this allows the calcium phosphate to
come into contact with extracellular matrix constituents,
triggering the formation of mature crystals of hydroxyap-
atite [24].
Apoptosis The extrusion of matrix vesicles by VSMCs and
related osteogenic cells may be partly stimulated when
these cells undergo apoptosis, leading to apoptotic bodies,
which behave in a similar fashion [24]. Apoptosis may
itself result from a variety of factors, including the action of
TNF-α and two members of the TNF superfamily, namely:
(1) receptor activator of nuclear factor kappa B (NF-κB)
(RANK) ligand (RANKL); and (2) TNF-related apoptosis-
inducing ligand (TRAIL). The actions of both of these are
inhibited by the glycoprotein, osteoprotegerin. Both the
apoptotic cells and the surrounding matrix may become
calcified.
Other cellular processes involved in calcification
of the arterial wall
Degradation of elastin Degradation of elastin occurs
during the development of arteriosclerosis. It may be the
































Fig. 2 Schematic diagram
indicating some of the multiple
processes likely to be
involved in ossification of the
media of arterial walls in
diabetes. Red, inhibitors of
calcification/ossification. MSCs,
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elastin, however, collagen becomes the principal extracel-
lular component of the arterial wall, which becomes stiffer
as a result, especially when collagen becomes glycated as in
diabetes mellitus [25, 26]. Elastin degradation products may
facilitate the process of calcification. Thus rat fibroblasts
exposed to elastin degradation products and TGF-β become
osteogenic and produce Cbfa1, osteocalcin, alkaline phos-
phatase and osteoprotegerin [27].
Neovascularisation New blood vessel formation is a key
part of endochondral ossification, as well as the calcifica-
tion that occurs in heart valves [28]. These new vessels
derive from pericytes, as well as from other cells of
mesenchymal lineage that are able to de-differentiate,
including VSMCs. The key factor promoting neovascular-
isation is thought to be VEGF, although it is also promoted
by bone sialoprotein and activin-A [21]. Recent evidence
shows that production of VEGF, at least in developing
bone, is itself triggered by production of hypoxia-inducible
factor-1α by osteoblasts [29].
Phosphate uptake VSMCs may also undergo calcification
through a process that is independent of apoptosis. Li and
colleagues have demonstrated that this can be mediated
through intracellular accumulation of phosphate through the
action of the sodium-dependent phosphate co-transporter,
solute carrier family 20 (phosphate transporter), member 1
(PIT-1) [30]. Intracellular phosphate stimulates the activity
of Cbfa1, which is an essential transcriptional factor for
osteoblast differentiation.
Factors known to influence the development
of osteogenic cells and vascular calcification
Fetuin-A Fetuin-A is an acute-phase glycoprotein that is
synthesised in the liver and acts as a carrier for growth factors
[31]. It also inhibits the actions of BMP-2. A powerful
inhibitor of hydroxyapatite formation, fetuin-A limits
matrix vesicle formation. In addition, it reduces apoptosis
and enhances phagocytosis (and hence inactivation) of
matrix vesicles by VSMCs. Reduced synthesis of fetuin-A
is a major factor leading to increased arterial calcification in
chronic kidney disease [11]. Polymorphisms in the gene
encoding fetuin-A are associated with poor cardiovascular
outcome; indeed, an inverse correlation has been demon-
strated between circulating concentrations of fetuin-A and
cardiovascular and all-cause mortality in man [32].
Matrix Gla protein Matrix Gla protein (MGP) is present in
VSMCs and, like osteocalcin, is one of a family of mineral-
binding proteins that contain γ-carboxyglutamic acid,
which has a high affinity for hydroxyapatite. MGP inhibits
induction of alkaline phosphatase by BMPs [33]. MGP-
deficient mice demonstrate extensive endochondral bone
formation in the arterial wall, as well as generalised
calcification of cartilage. In rats, inhibition of gamma-
carboxylation of MGP by warfarin is an established animal
model of vascular calcification. There is evidence of
complex coordination of the actions of fetuin A, MGP
and other factors in the release of calcium and phosphate
accompanying bone lysis [34].
Osteopontin Osteopontin (also known as bone sialoprotein-1)
is a phosphoprotein secreted by a range of cell types (including
pre-osteoblasts, osteoblasts and osteoclasts) and which has a
correspondingly wide range of biological functions. It is a
major constituent of bone matrix and has been shown to
inhibit calcification by adhering to calcium apatite crystals
[35]. However, it also stimulates osteoclast migration by
binding to αvβ3-integrin expressed on the osteoclast cell
surface. Patients with type 2 diabetes and calcification of
peripheral arteries display higher circulating concentrations
of osteopontin; the protein has also been found in increased
amounts in the arterial wall of human diabetic patients and
experimental animal models of diabetes [36].
Osteoprotegerin and its ligands, RANKL and TRAIL RANKL
is a polypeptide hormone that leads to increased produc-
tion of the nuclear transcription factor, NF-κB, which in
turn leads to maturation of pre-osteoclasts. Activation of
this pathway is thought to be central to bone break-down,
both in normal bone remodelling and in a wide variety of
pathological states [37, 38]. This process, however, is
modulated by a parallel action on osteoblasts, resulting in
production of osteoprotegerin, which has structural simi-
larity to the RANK receptor to which RANKL binds.
Osteoprotegerin thus acts as a decoy receptor and
effectively limits the action of RANKL. RANKL is a
member of the TNF superfamily. Its production is
regulated by TNF-α and other pro-inflammatory cyto-
kines, including IL-1β and IL-6. TRAIL is another
member of the TNF superfamily and induces apoptosis
of osteogenic cells in the arterial wall (see above). The
action of TRAIL, like that of RANKL, is inhibited by
osteoprotegerin.
The observation by Bucay and colleagues [39] that
osteoprotegerin-deficient mice not only had osteoporosis,
but also extensive MAC of the aorta and renal arteries, led
to the concept that the RANKL/osteoprotegerin signalling
pathway may be intimately involved in calcification of the
arterial wall, as well as in the regulation of bone turnover.
Osteoprotegerin and osteoprotegerin mRNA, as well as
TRAIL, have been observed to co-localise with areas of
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calcification in arterial wall, although levels of RANKL
were much lower [40]. RANKL production is closely
linked to that of TNF-α and other pro-inflammatory
cytokines, and TNF-α is known to mediate the response
of pericytes to inflammation by stimulating the formation of
BMPs. Nevertheless, a role for RANKL has not yet been
clearly established in the pathogenesis of arterial calcifica-
tion, even though circumstantial evidence suggesting its
involvement is very strong [7]. BMPs increase the levels of
RANKL and suppress osteoprotegerin [17]. RANKL has
also been shown to increase aortic calcification in vitro
through enhanced MSX and wingless-type MMTV integra-
tion site (WNT) signalling, the pathway that mediates the
effects of oxidative stress; this effect, moreover, was
abolished by the TNF antagonist, infliximab [41]. Recent
evidence has demonstrated that calcification of VSMCs, in
vivo and in vitro, is enhanced by RANKL, apparently
through a pathway that is dependent on RANK, NFκB and
BMP-4 [42].
While osteoprotegerin may therefore antagonise any
direct action of RANKL, it is possible that its dominant
protective effects in MAC are twofold: (1) suppression of
osteoclast activation by RANKL and hence reduced
liberation of calcium and phosphate from bone into the
circulation; and (2) inhibition of apoptosis of osteogenic
cells by TRAIL [10, 39]. Osteoprotegerin has also been
shown to accumulate in the arterial wall in diabetes, which
may reflect a compensatory mechanism or result from the
actions of pro-inflammatory cytokines [43].
Nitric oxide Nitric oxide has been shown to inhibit
calcification and osteoblastic transformation of VSMCs in
vitro, an effect that has been shown to be mediated through
inhibition of the actions of TGF-β and its downstream
effects on the phosphorylation of SMAD proteins and of
plasminogen activator inhibitor-1 [44].
HDL The administration of HDL to CVCs in vitro reduces
alkaline phosphatase activity (a marker of osteogenic
transformation of CVCs by BMPs), including that stimu-
lated by pro-inflammatory cytokines IL-1β and IL-6.
Prolonged administration of HDL to CVCs reduces
calcification [45].
Intra-arterial forces Interestingly, the increasing intra-
arterial systolic pressure that characterises arteriosclerosis
can itself augment the process of calcification. Thus levels
of NFκB and BMPs are enhanced by increased pressure
applied to endothelial cells in vitro [46]. External force has
also been shown to increase RANKL production by
osteoblasts, with particular changes induced by changes in
cyclical or oscillatory forces [47].
Chronic kidney disease
Arterial calcification is common in established renal failure,
with the main aetiological factors being vitamin D
deficiency (and associated secondary hyperparathyroidism,
which increases bone break-down) and hyperphosphatae-
mia [11]. Vitamin D deficiency and elevated parathyroid
hormone lead to increased levels of RANKL. Phosphate is
the key trigger for the formation of calcium phosphate in
matrix vesicles and non-apoptotic osteogenic cells. Loss of
the calcification inhibitor, fetuin-A, with declining GFR has
also been implicated [11].
It is also established that chronic kidney disease is
associated with increased circulating concentrations of
osteoprotegerin, which correlate with increased arterial
calcification and with increased cardiovascular and all-
cause mortality [48]. Excretion of hydroxyproline is
increased in patients with type 2 diabetes and micro-
albuminuria, suggesting increased bone turnover through
activation of osteoclasts by RANKL [49]. Similarly,
elevated circulating concentrations of osteoprotegerin
(reflecting activation of the RANKL/osteoprotegerin path-
way) have been shown in type 1 and type 2 diabetes
complicated by albuminuria [50]. Moreover, urinary albu-
min excretion in patients with diabetes is associated with
calcification of coronary and peripheral arteries [51].
Factors that potentiate arterial wall calcification
in diabetes
Metabolic and hormonal factors Intracellular glucose
induces tissue damage through four discrete mechanisms:
(1) activation of the polyol pathway resulting in increased
oxidative stress; (2) induction of an inflammatory response
by AGE; (3) activation of the protein kinase-C pathway,
leading to decreasing nitric oxide and increasing
endothelin-1; and (4) stimulation of N-acetyl glucosamine
via the hexosamine pathway, which causes increased
plasminogen activator inhibitor-1 and TGF-β [52]. Each
and all of these could lead to activation of the processes
leading to upregulation of the pathways that promote
calcification of the arterial wall. Recently, it was suggested
that insulin (or selective insulin resistance) may be directly
involved in the process of arterial calcification [43]. The
association is complex, since insulin can promote and
inhibit the calcification process, depending on cellular
responsiveness [43, 53].
Activation of the RANKL/osteoprotegerin signalling path-
way Abundant epidemiological and clinical data show that
diabetes is associated with increased circulating concen-
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trations of osteoprotegerin and that these correlate with
arterial calcification, clinical cardiovascular disease and all-
cause mortality rates in both cross-sectional and prospective
studies [54–58]. Serum concentrations of osteoprotegerin in
diabetes correlate with systolic blood pressure and bra-
chial–ankle pulse wave velocity (as a measure of arterial
wall stiffness) [59]. While it has been generally accepted
that increased concentrations of osteoprotegerin reflect
generalised activation of the RANKL/osteoprotegerin sys-
tem, Secchiero and colleagues [60] found that although
osteoprotegerin was increased in patients with diabetes,
total RANKL concentrations were not and free RANKL, in
fact, was significantly reduced. This observation awaits
confirmation now that assays for RANKL are more readily
available.
Circulating concentrations of osteoprotegerin have been
shown to be particularly elevated when diabetes is
accompanied by microvascular complications, such as
microalbuminuria and retinopathy [50]. This may reflect a
generalised process mediated, at least in part, by increased
activity of the RANKL/osteoprotegerin pathway and linked
to widespread endothelial changes. However, the relation-
ship between osteoprotegerin concentrations and both
retinopathy and proteinuria may not be directly causal.
The occurrence of proteinuria and retinopathy is closely
linked to that of DSN, with strong circumstantial evidence
suggesting that DSN may promote arterial calcification. A
significant contribution by DSN would also explain the
observation that MAC is most marked in the distal arteries,
as originally noted by Mönckeberg.
Distal symmetrical neuropathy
Sensory neuropathy Arterial calcification was noted in the
feet of 15 of 20 patients with severe diabetic neuropathy
[61] and was greater in patients with neuropathy than in
controls [62]. Neuropathy was also more prevalent in a
Veterans Administration population with arterial calcifica-
tion than in those without [63]. Psyrogiannis and colleagues
reported that calcification was present in 40% of people
whose diabetes was complicated by neuropathy [51].
Arterial calcification is also increased in other conditions
associated with DSN, although not to as great an extent as
in diabetes.
Other circumstantial evidence indicating the possible
importance of neuropathy in the pathogenesis of arterial
calcification is the arterial calcification observed in radio-
logical images of 80% to 90% of patients who had or had
previously had acute Charcot’s disease; a higher percentage
than in any other clinical group studied [64]; Acute
Charcot’s foot is a complication of DSN, and which is
associated with prolonged inflammation. Such inflamma-
tion could increase the prevalence of calcification through
increased levels of pro-inflammatory cytokines and the
RANKL/osteoprotegerin system [65]. Interestingly, arterial
calcification has also been shown to be increased in Paget’s
disease of bone, a condition that is also characterised by
increased RANKL levels and increased bone turnover [66].
Autonomic neuropathy It has long been suspected that
arterial calcification may be the result of autonomic
denervation. If so, this could explain the association with
sensorimotor DSN, as autonomic neuropathy and DSN
commonly co-exist in patients with diabetes. The most
impressive evidence for involvement of the autonomic
nervous system comes from the work of Goebel and
Fuessel [67], who studied the prevalence and incidence of
arterial calcification following unilateral and bilateral
lumbar sympathectomy for critical ischaemia in 60 patients,
of whom 19 had diabetes. The seemingly clear association
between sympathectomy and the onset or worsening of
arterial calcification on the treated side(s) strongly impli-
cates autonomic denervation, provided lumbar sympathec-
tomy can be assumed not to damage somatic, as well as
sympathetic nerves.
Others have shown associations between clinical signs of
autonomic dysfunction and arterial calcification in cross-
sectional studies, but great care is needed when interpreting
conventional tests used to define autonomic neuropathy in
patients who have arterial calcification. Impairment of
vasoconstriction may be solely the result of structural
changes in the arterial wall and need not necessarily
indicate loss of sympathetic innervation. Similarly, the
presence of arterial calcification could result in tachycardia,
and both this and the systolic hypertension associated with
arterial calcification could lead to reduced sinus arrhythmia,
which is conventionally interpreted as a sign of vagal
denervation of the heart. This may explain the relatively
poor performance of tests of cardiovascular autonomic
neuropathy in younger people with type 1 diabetes, when
compared with pupillometry [68]. And although Forst and
colleagues [69] observed a highly significant association
between MAC and autonomic neuropathy identified by loss
of sweat responses as well as by abnormal cardiovascular
reflexes in diabetes, Mayfield et al. [63] found that the
results of cardiovascular autonomic function tests did not
fully explain the increased mortality rates associated with
MAC.
Role of neuropeptides Any potentiation of arterial calcifi-
cation by DSN is likely to be mediated through loss of
neuropeptides, and especially neuropeptides of the calcito-
nin family, i.e. calcitonin gene-related peptide (CGRP), islet
amyloid polypeptide (amylin), adrenomedullin and inter-
medin, all of which are known to be important in the
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regulation of bone metabolism [70]. Of these, the prime
candidate at the level of the peripheral nerve is CGRP.
Experimental diabetes complicated by neuropathy has been
shown to result in downregulation of CGRP in nerves from
rats and mice [71, 72]. In human diabetes, neuropathy has
been shown in one small study to be associated with
reduced nitric oxide synthase in bone, as well as with a
trend towards reduction of CGRP [73].
CGRP has trophic and vasodilatory properties [74] and
is known to be an important regulator of bone at the level of
the osteoblast, with CGRP depletion leading to decreased
bone formation [75]. Like calcitonin, CGRP also inhibits
osteoclast maturation [76]. Both calcitonin and CGRP have
been shown to inhibit the maturation of osteoclasts induced
by RANKL [77]. Nevertheless, CGRP can also inhibit the
synthesis of osteoprotegerin by osteoblasts, suggesting a
bimodal, autoregulatory, action [78]. This is echoed by the
finding that CGRP (as well as substance P) can induce in
vitro formation of the pro-inflammatory cytokines, IL-1,
IL-6 and TNF-α, in human dental pulp cells [79].
CGRP may also play a key part in the healing of
ligamentous damage in laboratory animals [67], a finding
particularly relevant to acute Charcot’s disease of diabetes.
Hitherto, there has been no explanation for the increased
dislocation of joints, which together with bone inflamma-
tion and fracture, characterises this condition. However,
impaired ligamentous strength and healing as a result of
underlying neuropathy and resultant loss of CGRP would
provide such an explanation.
Neuropeptides and the sympathetic nervous system Bone
and periosteum are richly innervated by CGRP-containing
nerve fibres and run in close proximity to a dense mesh of
sympathetic (tyrosine hydroxylase-positive) and sensory
(NF200+) nerve terminals [80]. It is also thought that
nerves in bone, which contain CGRP, substance P and
vasoactive intestinal polypeptide, may relay central signals
resulting from the action of leptin on the hypothalamus
[75]. Leptin stimulates sympathetic β2-adrenergic signal-
ling, which inhibits osteoblastic function and favours bone
resorption [81]. β2-Adrenergic stimulation of a mouse bone
marrow cell model with isoprenaline resulted in increased
osteoclast activation via the action of RANKL, a process
inhibited by administration of osteoprotegerin [82]. Neuro-
peptide Y is a co-transmitter with noradrenaline in
sympathetic nerve terminals and inhibits the effect of the
β2-adrenergic agonist, isoprenaline, in stimulating bone
resorption. It does not, however, inhibit the stimulatory
effect of RANKL or 1,25-dihydroxycholecalciferol on
osteoclasts [83]. Although knowledge of the processes
involved is patchy, the evidence suggests close integration
of neuropeptides and the sympathetic nervous system in the
regulation of bone formation and turnover. Thus although
virtually all the available evidence relates to bone, similar
relationships could be involved in the development of
arterial calcification, especially given that the signalling
pathways are so similar.
Endocannabinoids and the sympathetic nervous system The
final pathway possibly involved in the development of MAC
is that of endocannabinoids. Here, once again, the available
evidence comes from work on bone. Two endogenous
endocannabinoids, anandamide and 2-arachidonoylglycerol
are present in osteoblasts and osteoclasts, and it is likely that
they modulate the effect of the sympathetic nervous system on
bone resorption. Endocannabinoids induce production of NF-
κB in bone marrow dendritic cells [84].
Implications of role of neuropathy in causing MAC
The involvement of the nervous system, whether somatic or
autonomic, in promoting MAC would explain the distal
distribution of calcification in diabetes and other disorders
of denervation. It also implies that the factors triggering
MAC may be both local and systemic, even though
systemic factors (such as hyperglycaemia, hyperlipidaemia,
reactive oxygen species, circulating pro-inflammatory cyto-
kines, phosphate retention) are the principal ones consid-
ered hitherto as a cause of MAC. Thus, the changes
triggered by neuropathy will be largely confined to the
tissues affected, regardless of whether the effect of
denervation is exerted on the arterial wall (with increased
RANKL, for example, or reduced osteoprotegerin being
triggered by loss of CGRP) or whether the primary effect is
on the bone. If the primary effect is on the bone, increased
bone resorption could trigger calcification by releasing
calcium and phosphate ions, which also has a predomi-
nantly local, rather than systemic effect.
DSN as an independent risk factor for cardiovascular
disease in diabetes
If DSN has a role in the pathogenesis of arterial
calcification and explains the distal distribution of calcifi-
cation observed in diabetes, it is possible that it also has an
independent effect on cardiovascular risk. Cardiovascular
risk would be increased by rising arterial systolic pressure
and widened pulse pressure, which results from loss of
compliance in the stiffened wall. Ono and colleagues [85]
reported that elevation of the ankle–brachial pressure index
(as a marker of arteriosclerosis) was associated with all-
cause and cardiovascular mortality rates in a population of
patients (with and without diabetes) on haemodialysis.
Others have also noted the close relationship between
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arterial calcification, pulse wave velocity and cardiovascu-
lar mortality rates in chronic kidney disease patients [86].
DSN is not generally regarded as a risk factor for
cardiovascular disease, yet a strong independent relation-
ship was recently observed between peripheral sensory
neuropathy and pulse pressure for cardiovascular and all-
cause mortality rates in the Eurodiab study of type 1
diabetes [87]. This observation confirms earlier observa-
tions made by Forsblom et al. [88] in patients with type 2
diabetes and by Coppini et al. [89] in a mixed population.
However, no association was observed between cardiovas-
cular mortality rates and sensory neuropathy in the UK
Prospective Diabetes Study, and between all-cause and
cardiovascular mortality rates and the presence of DSN in
newly diagnosed type 2 diabetes at presentation (I. Stratton,
National Screening Programmes for Diabetic Retinopathy,
Cheltenham General Hospital, Cheltenham, UK, personal
communication). An association between mortality rates and
neuropathy does not appear to have been sought in the Danish
[90], WHO Multinational [91] and Pittsburgh [92] studies.
Nevertheless, the possibility that DSN confers an indepen-
dent cardiovascular risk merits further study. If it is
confirmed, we suggest that it is likely to result largely from
a neuropathy-mediated effect on cardiovascular calcification.
Therapeutic implications
Improved understanding of the causes and effects of MAC
would have immediate clinical and therapeutic implica-
tions. Specific interventions to prevent or reverse arterial
calcification might include the use of antagonists to TNF-α
and RANKL, such as infliximab, etanercept and denosu-
mab. However, agents currently in more widespread
clinical use might also have a role. Thus HMG-Co-A
reductase inhibitors (statins) have been reported to inhibit
phosphate-induced apoptosis of smooth muscle cells [93],
but the evidence is ambiguous [94, 95] and simvastatin did
not reverse established arterial calcification in one human
study [96]. The potential benefit of peroxisome proliferator-
activated receptor (PPAR)γ agonists has yet to be fully
explored, although their use is known to be associated with
decreased expression of pro-inflammatory cytokines and
they have also been reported to inhibit neovascularisation.
However, the known tendency of PPARγ to augment bone
break-down could potentially increase arterial calcification.
Finally, the use of ACE inhibitors and angiotensin receptor
blocking agents has been shown to be associated with
reduced progression of coronary artery calcification in type
1 diabetes [97], an apparent effect that requires further
study.
Recent work has also highlighted the potentially
catastrophic adverse effect of MAC on cardiovascular
compensatory mechanisms, especially in patients under-
going haemodialysis. Thus, dialysis has been shown to
be associated with a major reduction in myocardial
function [98] and distal limb oxygenation [99], both of
which could contribute to the very high mortality rates
associated with dialysis, as well as to its close association
with the onset of foot disease in diabetes and with
amputation [100]. Strategies to reduce the impact of these
consequences of dialysis are urgently needed and should
include careful review of the benefits and costs of aggressive
management of systolic hypertension patients with MAC.
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